O	0	6	Effect
O	7	9	of
O	10	19	different
O	20	25	doses
O	26	28	of
B-intervention	29	38	metformin
O	39	41	on
B-condition	42	47	serum
I-condition	48	60	testosterone
I-condition	61	64	and
I-condition	65	72	insulin
O	73	75	in
O	76	79	non
O	79	80	-
O	80	88	diabetic
O	89	94	women
O	95	99	with
O	100	106	breast
O	107	113	cancer
O	113	114	:
O	115	116	a
O	117	127	randomized
O	128	133	study
O	133	134	.

O	135	139	This
O	140	142	is
O	143	144	a
O	145	155	randomized
O	156	166	controlled
O	167	172	trial
O	173	175	to
O	176	180	test
O	181	184	the
O	185	191	effect
O	192	194	of
O	195	204	different
O	205	210	doses
O	211	213	of
O	214	223	metformin
O	224	226	in
O	227	235	patients
O	236	240	with
O	241	247	breast
O	248	254	cancer
O	255	258	and
O	259	266	without
O	267	275	diabetes
O	275	276	,
O	277	281	with
O	282	285	the
O	286	289	aim
O	290	292	of
O	293	302	modifying
O	303	306	the
O	307	315	hormonal
O	316	319	and
O	320	329	metabolic
O	330	340	parameters
O	341	347	linked
O	348	350	to
O	351	357	breast
O	358	364	cancer
O	365	374	prognosis
O	374	375	.

O	376	384	Analysis
O	385	387	of
O	388	391	the
O	392	399	results
O	400	407	suggest
O	408	412	that
O	413	416	the
O	417	421	dose
O	422	424	of
O	425	429	1500
O	430	432	mg
O	432	433	/
O	433	434	d
O	435	437	of
O	438	447	metformin
O	448	454	causes
O	455	456	a
O	457	468	significant
O	469	478	reduction
O	479	481	of
O	482	489	insulin
O	490	493	and
O	494	506	testosterone
O	507	512	serum
O	513	519	levels
O	519	520	.

O	521	526	Serum
O	527	533	levels
O	534	536	of
O	537	544	insulin
O	545	548	and
O	549	561	testosterone
O	562	565	may
O	566	572	affect
O	573	577	both
O	578	584	breast
O	585	591	cancer
O	592	593	(
O	593	595	BC
O	595	596	)
O	597	606	incidence
O	607	610	and
O	611	620	prognosis
O	620	621	.

O	622	631	Metformin
O	632	639	reduces
O	640	653	hyperglycemia
O	654	657	and
O	658	665	insulin
O	666	672	levels
O	673	675	in
O	676	684	patients
O	685	689	with
O	690	698	diabetes
O	698	699	.

O	700	702	In
O	703	708	women
O	709	716	without
O	717	725	diabetes
O	726	729	and
O	730	734	with
O	735	745	polycystic
O	746	751	ovary
O	752	760	syndrome
O	760	761	,
O	762	771	metformin
O	772	778	lowers
O	779	783	both
O	784	791	insulin
O	792	795	and
O	796	808	testosterone
O	809	815	levels
O	815	816	.

O	817	825	Patients
O	826	830	with
O	831	839	diabetes
O	840	843	who
O	844	847	are
O	848	855	treated
O	856	860	with
O	861	870	metformin
O	871	877	showed
O	878	879	a
O	880	885	lower
O	886	890	risk
O	891	893	of
O	894	900	cancer
O	900	901	;
O	902	903	a
O	904	914	protective
O	915	921	effect
O	922	924	of
O	925	934	metformin
O	935	939	also
O	940	943	was
O	944	952	observed
O	953	956	for
O	957	959	BC
O	959	960	.

O	961	969	Recently
O	969	970	,
O	971	978	studies
O	979	981	on
O	982	991	metformin
O	992	995	use
O	996	999	for
O	1000	1010	prevention
O	1011	1013	or
O	1014	1023	treatment
O	1024	1026	of
O	1027	1029	BC
O	1030	1034	have
O	1035	1039	been
O	1040	1048	proposed
O	1049	1051	in
O	1052	1060	patients
O	1061	1064	who
O	1065	1068	are
O	1069	1072	not
O	1073	1081	diabetic
O	1081	1082	.

O	1083	1086	The
O	1087	1090	aim
O	1091	1093	of
O	1094	1097	the
O	1098	1105	present
O	1106	1111	study
O	1112	1115	was
O	1116	1118	to
O	1119	1123	test
O	1124	1127	the
O	1128	1134	effect
O	1135	1137	of
O	1138	1147	different
O	1148	1153	doses
O	1154	1156	of
O	1157	1166	metformin
O	1167	1169	on
O	1170	1175	serum
O	1176	1182	levels
O	1183	1185	of
O	1186	1193	insulin
O	1194	1197	and
O	1198	1210	testosterone
O	1211	1213	in
O	1214	1219	those
B-eligibility	1220	1234	postmenopausal
I-eligibility	1235	1243	patients
I-eligibility	1244	1248	with
I-eligibility	1249	1255	breast
I-eligibility	1256	1262	cancer
I-eligibility	1263	1266	and
I-eligibility	1267	1274	without
I-eligibility	1275	1283	diabetes
I-eligibility	1284	1287	who
I-eligibility	1288	1292	have
I-eligibility	1293	1298	basal
I-eligibility	1299	1311	testosterone
I-eligibility	1312	1318	levels
I-eligibility	1319	1320	â‰¥
I-eligibility	1320	1321	0
I-eligibility	1321	1322	.
I-eligibility	1322	1324	28
I-eligibility	1325	1327	ng
I-eligibility	1327	1328	/
I-eligibility	1328	1330	mL
O	1331	1332	(
O	1332	1338	median
O	1339	1344	value
O	1344	1345	)
O	1345	1346	.

O	1347	1348	A
O	1349	1354	total
O	1355	1357	of
B-total-participants	1358	1361	125
O	1362	1370	eligible
O	1371	1376	women
O	1377	1381	were
O	1382	1391	initially
O	1392	1399	invited
O	1400	1402	to
O	1403	1407	take
O	1408	1417	metformin
O	1418	1421	500
O	1422	1424	mg
O	1424	1425	/
O	1425	1426	d
O	1427	1430	for
O	1431	1432	3
O	1433	1439	months
O	1439	1440	.

O	1441	1444	The
B-total-participants	1445	1448	108
O	1449	1454	women
O	1455	1458	who
O	1459	1468	completed
O	1469	1472	the
O	1473	1478	first
O	1479	1480	3
O	1481	1487	months
O	1488	1492	were
O	1493	1500	invited
O	1501	1503	to
O	1504	1512	continue
O	1513	1516	the
O	1517	1522	study
O	1523	1527	with
O	1528	1537	metformin
O	1538	1542	1000
O	1543	1545	mg
O	1545	1546	/
O	1546	1547	d
O	1548	1549	(
O	1549	1552	500
O	1553	1555	mg
O	1556	1561	twice
O	1562	1563	a
O	1564	1567	day
O	1568	1569	[
O	1569	1570	b
O	1570	1571	.
O	1571	1572	i
O	1572	1573	.
O	1573	1574	d
O	1574	1575	.
O	1575	1576	]
O	1576	1577	)
O	1578	1581	for
O	1582	1583	1
O	1584	1589	month
O	1589	1590	.

O	1591	1594	The
O	1595	1600	women
O	1601	1605	were
O	1606	1610	then
O	1611	1621	randomized
O	1622	1626	into
O	1627	1628	2
O	1629	1635	groups
O	1635	1636	,
O	1637	1640	and
O	1640	1641	,
O	1642	1645	for
O	1646	1649	the
O	1650	1660	subsequent
O	1661	1662	5
O	1663	1669	months
O	1669	1670	,
O	1671	1672	1
O	1673	1678	group
O	1679	1688	increased
O	1689	1692	the
O	1693	1697	dose
O	1698	1700	by
O	1701	1707	taking
O	1708	1717	metformin
O	1718	1722	1500
O	1723	1725	mg
O	1725	1726	/
O	1726	1727	d
O	1728	1729	(
O	1729	1732	500
O	1733	1735	mg
O	1736	1737	3
O	1738	1743	times
O	1744	1745	a
O	1746	1749	day
O	1750	1751	[
O	1751	1752	t
O	1752	1753	.
O	1753	1754	i
O	1754	1755	.
O	1755	1756	d
O	1756	1757	.
O	1757	1758	]
O	1758	1759	)
O	1759	1760	,
O	1761	1764	and
O	1765	1768	the
O	1769	1774	other
O	1775	1780	group
O	1781	1790	continued
O	1791	1795	with
B-control	1796	1805	metformin
I-control	1806	1810	1000
I-control	1811	1813	mg
I-control	1814	1815	/
I-control	1815	1816	d
O	1817	1818	(
O	1818	1821	500
O	1822	1823	[
O	1823	1824	b
O	1824	1825	.
O	1825	1826	i
O	1826	1827	.
O	1827	1828	d
O	1828	1829	.
O	1829	1830	]
O	1830	1831	)
O	1831	1832	.

O	1833	1834	A
O	1835	1840	total
O	1841	1843	of
B-total-participants	1844	1846	96
O	1847	1852	women
O	1853	1862	completed
O	1863	1866	the
O	1867	1872	study
O	1872	1873	:
B-intervention-participants	1874	1876	43
O	1877	1882	women
O	1883	1891	received
O	1892	1896	1500
O	1897	1899	mg
O	1899	1900	/
O	1900	1901	d
O	1901	1902	,
O	1903	1906	and
B-control-participants	1907	1909	53
O	1910	1915	women
O	1916	1924	received
O	1925	1929	1000
O	1930	1932	mg
O	1932	1933	/
O	1933	1934	d
O	1934	1935	.

O	1936	1939	The
O	1940	1945	women
O	1946	1949	who
O	1950	1954	took
O	1955	1959	1500
O	1960	1962	mg
O	1962	1963	/
O	1963	1964	d
O	1965	1971	showed
O	1972	1973	a
O	1974	1985	significant
O	1986	1995	reduction
O	1996	1998	of
B-outcome	1999	2006	insulin
I-outcome	2007	2012	level
O	2012	2013	,
B-outcome	2014	2018	HOMA
I-outcome	2018	2019	-
I-outcome	2019	2021	IR
I-outcome	2022	2027	index
O	2028	2029	(
O	2029	2040	homeostasis
O	2041	2046	model
O	2047	2057	assessment
O	2057	2058	-
O	2058	2065	insulin
O	2066	2076	resistance
O	2077	2082	index
O	2082	2083	)
O	2083	2084	,
B-outcome	2085	2097	testosterone
I-outcome	2098	2103	level
O	2103	2104	,
O	2105	2108	and
B-outcome	2109	2113	free
I-outcome	2114	2122	androgen
I-outcome	2123	2128	index
O	2129	2137	compared
O	2138	2142	with
O	2143	2148	women
O	2149	2156	treated
O	2157	2161	with
O	2162	2166	1000
O	2167	2169	mg
O	2169	2170	/
O	2170	2171	d
O	2171	2172	.

O	2173	2178	After
O	2179	2188	treatment
O	2189	2193	with
O	2194	2198	1500
O	2199	2201	mg
O	2201	2202	/
O	2202	2203	d
O	2203	2204	,
O	2205	2208	the
B-outcome	2209	2216	insulin
I-outcome	2217	2222	level
O	2223	2232	decreased
O	2233	2235	by
O	2236	2238	25
O	2238	2239	%
O	2240	2243	and
O	2244	2247	the
B-outcome	2248	2260	testosterone
I-outcome	2261	2266	level
O	2267	2276	decreased
O	2277	2279	by
O	2280	2282	23
O	2282	2283	%
O	2283	2284	.

O	2285	2289	Both
O	2290	2295	these
O	2296	2303	changes
O	2304	2309	might
O	2310	2314	have
O	2315	2316	a
O	2317	2327	prognostic
O	2328	2338	importance
O	2338	2339	.
